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Abstract 
Background: Recent guidelines have recommended vancomycin trough levels of 15–20 mg/L for treatment of seri-
ous infections caused by methicillin-resistant Staphylococcus aureus (MRSA). However, high trough levels may increase 
risk of nephrotoxicity and mortality, and high vancomycin trough levels have not been well studied. This study was 
designed to combine safety and efficacy results from independent studies and to compare between high and low 
vancomycin trough levels in the treatment of MRSA-infected patients using meta-analysis.
Methods: From 19 eligible studies, 9 studies were included in meta-analysis to compare clinical success between 
high and low vancomycin trough levels, while 10 and 11 studies met criteria for comparing trough levels and nephro-
toxicity and trough levels and mortality, respectively. The PubMed/Medline, Web of Science, and Scopus databases, 
and hand searching were used to identify eligible studies dated up to March 2016. Of 2344 subjects with MRSA infec-
tion, 1036 were assigned to trough levels ≥15 mg/L and 1308 to trough levels <15 mg/L.
Results: High vancomycin trough levels were found to be associated with risk of nephrotoxicity (odds ratio [OR] 2.14, 
95 % confidence interval [CI] 1.42–3.23 and adjusted OR 3.33, 95 % CI 1.91–5.79). There was no evidence of difference 
between high and low vancomycin trough levels for mortality (OR; 1.09; 95 % CI 0.75–1.60) or clinical success (OR 1.07; 
95 % CI 0.68–1.68).
Conclusion: In this study, high vancomycin trough levels were identified as an independent factor associated with 
risk of nephrotoxicity in MRSA-infected patients. Association between vancomycin trough levels and both adverse 
effects and clinical outcomes requires further study.
Keywords: Vancomycin trough levels, Clinical success, Mortality, Nephrotoxicity, Methicillin-resistant Staphylococcus 
aureus, Meta-analysis
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Background
Vancomycin was first approved for use in 1958 by the 
US Food and Drug Administration (FDA) for treat-
ing penicillin-resistant Staphylococcus aureus infection. 
Vancomycin continues to be widely used, particularly due 
to recent increases in incidence of serious methicillin-
resistant S. aureus (MRSA) infections. Although vanco-
mycin has been used for over 40 years, it still remains a 
standard treatment for infections caused by MRSA. How-
ever, reports began to appear in 2003 describing clinical 
failures of vancomycin treatment due to the emergence 
of MRSA with reduced vancomycin susceptibility [1, 2]. 
Since 2003, several similar studies have been published in 
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which vancomycin-susceptible MRSA strains were iden-
tified and clinical failure resulted, despite monitoring and 
maintenance of trough levels in the recommended range 
to ensure vancomycin efficacy [3, 4]. Since more than two 
decades ago and according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines [5, 6], vancomycin 
MICs have increased over time—a phenomenon that is 
referred to as vancomycin MIC creep [7, 8]. As a result 
of published studies demonstrating vancomycin treat-
ment failure in patients with S. aureus infections who had 
a vancomycin MIC ≥4 mg/L, the CLSI lowered pre-2006 
vancomycin MIC breakpoints by broth microdilution 
(BMD) from ≤4 to ≤2  µg/mL for susceptible strains of 
S. aureus.
Early target trough levels for vancomycin were 
5–10 mg/L, and then they were increased to 8–15 mg/L. 
Vancomycin trough levels of 15–20  mg/L (area under 
the curve [AUC]: minimum inhibitory concentration 
[MIC] ratio ≥400 in most patients if MIC is ≤1  mg/L) 
are recommended by the Infectious Diseases Society 
of America (IDSA) and the American Thoracic Society 
(ATS) in patients with normal renal function and serious 
infections [9, 10]. New guidelines and expert panel rec-
ommendations for vancomycin therapeutic drug moni-
toring (TDM) recommend trough levels of 15–20 mg/L 
to prevent development of resistance and improve 
clinical outcomes. Whether trough levels explain the 
apparent failure of vancomycin treatment remains con-
troversial. Some studies have shown higher troughs not 
to be associated with increased vancomycin efficacy 
in patients with MRSA infections [11–16], while oth-
ers studies did find association with increased efficacy 
[17–20]. The guideline suggests that vancomycin efficacy 
in invasive infections caused by MRSA is determined by 
adult pharmacokinetic and pharmacodynamic data that 
achieved AUC/MIC of ≥400 which correlates with van-
comycin trough levels of 15–20 μg/mL. Because an AUC/
MIC goal value is difficult to calculate and given the 
good comparability between AUC/MIC and vancomycin 
trough levels, trough levels are considered to be both the 
most accurate and the most practical method for thera-
peutic drug monitoring of vancomycin.
The new guidelines also warn that vancomycin nephro-
toxicity should be considered if serum creatinine concen-
tration increases greater than or equal to 0.5 mg/dL, or 
more than 50 % over the baseline value. Previously, most 
reports of acute kidney injury (AKI) were likely linked to 
impurities in vancomycin preparation, which was some-
times disparagingly referred to as ‘Mississippi mud’. How-
ever, in the 1960s, the purity of vancomycin preparation 
increased to 75  % with a further increase in purity to 
92–95 % in 1985 [10, 21]. As a result, impurities in vanco-
mycin preparation were no longer a concerned.
A recent meta-analysis found association between high 
vancomycin trough levels and nephrotoxicity in sub-
jects with Gram-positive infections and in patients with 
various other types of infections [22]. However, in that 
meta-analysis, the effect of vancomycin trough levels on 
nephrotoxicity and clinical outcomes in patients with 
MRSA infection was not investigated. It also remains 
unclear whether an increase in vancomycin trough levels 
could improve clinical outcomes of vancomycin treat-
ment in MRSA infections. As such, the aim of this study 
was to combine safety and efficacy results from inde-
pendent studies and to compare between high and low 
vancomycin trough levels in the treatment of MRSA-
infected patients using meta-analysis.
Methods
Data sources and search strategy
Multiple electronic databases including MEDLINE/Pub-
med, Web of Science, and Scopus, were searched for 
reports published up to March 2016. The search terms 
used included “vancomycin”, “trough levels”, “trough con-
centration”, “nephrotoxicity”, and “methicillin-resistant S. 
aureus”. The word vancomycin was also combined with 
other terms in various combinations. MeSH terms for 
“vancomycin” and “methicillin-resistant Staphylococ-
cus aureus” were also included in our PubMed search. 
In addition, a hand search of reference lists of selected 
studies and grey literature (conference proceedings, dis-
sertations, theses, and reports) was conducted to iden-
tify relevant studies not included in electronic databases. 
Abstract lists and conference proceedings from the 2007 
to 2015 scientific meetings of the Infectious Diseases 
Society of America, International Society for Infectious 
Diseases, American Society for Microbiology, and Euro-
pean Society of Clinical Microbiology and Infectious 
Diseases were also searched to identify possibly eligible 
studies (see Additional file  1). No language restrictions 
were applied for these searches.
Study selection
A single investigator (ST) screened the titles and abstracts 
of potentially eligible studies, and then examined the arti-
cles to determine whether they met the established inclu-
sion criteria. Selected articles were then double-checked 
in detail by the second investigator (PK). In the end, all 
selected articles were reviewed and approved by both 
investigators, with no disagreement between investiga-
tors regarding the eligibility of an article identified by one 
or the other investigator. All published and unpublished 
studies were included if they met the following criteria: 
(1) evaluated primary outcomes (i.e., nephrotoxicity, 
mortality and/or clinical success) of adult patients with 
MRSA infections; and, (2) the observed outcomes could 
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be extracted and classified into two trough levels. Papers 
were excluded if they were characterized by one or more 
of the following: (1) conducted in pediatric patients; (2) 
focused on treatment of MRSA-infected patients with 
vancomycin MIC of ≥2  mg/L; (3) we could not extract 
information relevant to only MRSA infections; or, (4) 
they were reviews, guidelines, editorials, or non-human 
research.
Data extraction and management
Data extraction and management for included studies 
were performed by the first investigator (ST). Both inves-
tigators (ST, PK) met to discuss data extraction findings 
and characteristics of each study for purposes of ensuring 
clear understanding of assessment criteria. The following 
information was extracted from each eligible study: the 
first author’s last name, year of publication, study loca-
tion, patient characteristic, study design, sample size 
(number of subjects in high and low trough groups), tim-
ing of vancomycin trough level measurement, duration 
of vancomycin therapy, concomitant nephrotoxic agent, 
outcomes and definitions of outcomes, ORs and 95 % CIs 
for each outcome, and covariates adjusted for in multi-
variable models (when they were available). The first 
investigator (ST) also screened and double-checked data 
for data entry errors.
In this meta-analysis, patients were analyzed according 
to their vancomycin trough levels, which were defined as 
<15  mg/L for low trough levels and ≥15  mg/L for high 
trough levels. For each eligible study, categories were 
recoded as follows: categories “<10” and “10–14  mg/L 
were collapsed into <15; “15–20 mg/L” was classified as 
≥15  mg/L; and, categories “<15” and “≥15  mg/L” were 
retained in their original category for all analyses. If the 
information was available, patients with trough level 
>20  mg/L were eliminated from analysis so we could 
focus only on the 15–20  mg/L range in high trough 
patients. For this study, serious MRSA infection was 
defined as a person with any one or more of the follow-
ing infections caused by MRSA: bacteremia, endocardi-
tis, osteomyelitis, meningitis, pneumonia, and/or central 
nervous system infection.
Data synthesis and analysis
A funnel plot was generated to assess funnel plot asym-
metry by plotting the standard error of the odds ratio 
on the vertical axis and the odds ratio on the horizontal 
axis, with degree of asymmetry tested by Egger’s test [23] 
and Begg’s test [24]. A p value <0.05 was considered to be 
statistically significant asymmetry. A forest plot was pro-
duced to show the odds ratio with 95 % CI of each study 
and the pooled odds ratio with the corresponding 95  % 
CI. Jackknife procedure-based sensitivity analysis was 
performed by omitting one study at a time to evaluate the 
effect of individual studies on the stability of the results.
Pooled odds ratio was calculated using the DerSimo-
nian and Laird random-effects model [25]. Greenland-
Robin variance formula was used to calculate confidence 
intervals of the pooled odds ratio. Heterogeneity among 
studies was evaluated using the Chi square based Q sta-
tistics (χ2), measure of inconsistency (I2), and between-
study variance (τ2). A p value <0.10 was considered to 
indicate statistically significant heterogeneity while 
I2  >  50  % was considered to indicate at least moderate 
heterogeneity. Trim and fill method [26, 27] was used to 
estimate overall effect size after adjusting for funnel plot 
asymmetry arising from publication bias [28]. All analy-
ses were performed using R software with meta package 
(R Foundation, Vienna, Austria) [29].
Results
The article selection process for this meta-analysis is 
shown in Fig.  1. The initial search comprising three 
online databases, hand searching and grey literature 
databases for reports published up to March 2016 yielded 
1170 articles. That list was narrowed to 35 potentially rel-
evant articles after a review of their titles and abstracts. 
After a more detailed review, an additional 16 articles 
were excluded. The remaining 19 reports fully satisfied 
the inclusion criteria and were included in the final anal-
ysis. All included studies were reported in the English 
language.
Of the 19 included studies, three studies had three 
categories of trough levels (<15, 15–20 and >20  mg/L), 
one study had four categories (<10, 10–14.9, 15–20 and 
>20 mg/L), and the remaining 15 studies had two trough 
levels (<15 and ≥15  mg/L). One hundred and twelve 
patients with trough level >20 mg/L were excluded from 
this meta-analysis. However these patients were later and 
temporarily included for purposes of comparing outcome 
results against the results and conclusion with these 
patients excluded (data not shown). Of 19 eligible studies, 
meta-analysis of nine studies was per formed to inves-
tigate the link between vancomycin trough levels and 
clinical success, while 10 and 11 studies met the criteria 
for investigating association between trough levels and 
nephrotoxicity and trough levels and mortality, respec-
tively. Three studies were available for analysis of the rela-
tionship between nephrotoxicity and vancomycin trough 
levels by combining adjusted OR estimates from multiple 
logistic regression analysis in order to adjust confounding 
variables of each included study.
The main characteristics of the studies included in this 
meta-analysis are presented in Table 1. Included studies 
were conducted and reported between 1999 and 2013. 
One thousand and thirty-six subjects were assigned to 
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the high trough group (trough levels ≥15 mg/L) and 1308 
subjects were assigned to the low trough group (trough 
levels <15  mg/L). Effect sizes of outcome measures for 
each included study are shown in Table 2.
The amount of heterogeneity among the included 
studies showed evidence of heterogeneity of ORs across 
the studies for nephrotoxicity (χ2  =  15.78, p  =  0.072, 
I2 = 43 % and τ2 = 0.17) and clinical success (χ2 = 18.4, 
p = 0.018, I2 = 56.5, and τ2 = 0.248); whereas heteroge-
neity was not found for mortality (χ2 = 12.69, p = 0.242; 
I2 = 21.2, and τ2 = 0.09) (Figs. 2, 3, 4). There was no evi-
dence of heterogeneity of adjusted OR among the three 
studies used to investigate the association between van-
comycin trough levels and nephrotoxicity (χ2  =  0.16, 
p = 0.92; I2 = 0 % and τ2 = 0).
In our study, risk of nephrotoxicity was significantly 
associated with high vancomycin trough levels (OR 2.14 
95  % CI 1.42–3.23; p  <  0.001). There was, however, no 
evidence of mortality decline (OR 1.09, 95  % CI 0.75–
1.60; p  =  0.64) or improved clinical success (OR 1.07, 
95  % CI 0.68–1.68; p  =  0.761) (Figs.  2, 3, 4). Strength 
of association between vancomycin trough levels and 
nephrotoxicity was measured by combining adjusted 
ORs and confounding variables were adjusted for in each 
included study (as described in the footnotes of Table 2). 
After combining the adjusted ORs, the main result was 
still significant. Specifically, the odds of nephrotoxicity 
occurring in MRSA-infected patients with trough lev-
els ≥15 mg/L were 3.33 times higher than patients with 
trough levels <15 mg/L (95 % CI 1.91–5.79; p < 0.0001).
For nephrotoxicity, none of the included studies influ-
enced the results to an extent that the conclusion would 
have changed. The jackknife sensitivity analysis with 
omitted one study at a time and reevaluated association 
between trough levels and nephrotoxicity, consistently 
showed that vancomycin trough levels were associated 
with risk of nephrotoxicity (Fig. 5a). The sensitivity analy-
sis also showed that the one-by-one exclusion of each 
study did not affect the conclusion of pooled effect size 
for either mortality or clinical success.
The funnel plot revealed some asymmetry for nephro-
toxicity and clinical success (Fig. 6a, c). Formal testing for 
publication bias relative to two outcomes (nephrotoxic-
ity—Begg’s test: p = 0.65 and Egger’s test: p = 0.62; and, 
mortality: Begg’s test: p = 0.82 and Egger’s test: p = 0.87) 
did not show statistical significance of asymmetry. 
These tests, however, yielded statistical significance of 
Potential relevant studies identified 
via database search (Pubmed, Web 
of Science, Scopus): 1170 articles
Potential relevant studies identified 
via other sources (reference lists of 
selected studies, conference 
proceedings, dissertations, theses, 
reports): 64 articles
35 article abstracts screened after 
removing duplicates
19 studies included in meta-analysis 
(n= 2344) 
16 articles excluded because they did not meet 
inclusion criteria
1199 articles excluded based on 
review of titles and abstracts 
Step 1: Review of article 
title and abstracts
Step 2: Full text and conference 
abstracts reviewed for more 
detailed evaluation
Fig. 1 Flow diagram of study selection process
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asymmetry for clinical success (Begg’s test: p = 0.095 and 
Egger’s test: p = 0.003).
Adjustment for funnel plot asymmetry using the trim 
and fill method did not change the pooled OR for mor-
tality (Fig.  6b). There was some funnel plot asymme-
try for both nephrotoxicity and clinical success, and the 
trim and fill method indicated that the true estimates of 
pooled OR for nephrotoxicity and clinical success may 
be 1.99 (95 % CI 1.33–2.96; p < 0.001) and 1.71 (95 % CI 
1.04–2.81; p = 0.034), respectively (Fig. 6a, c). However, 
after adjusting for funnel plot asymmetry, the conclu-
sion of this meta-analysis regarding nephrotoxicity was 
not changed, while there was a significant change in the 
conclusion for clinical success. The trim and fill method 
demonstrated significant association between high 
trough levels and clinical success, with the odds of clini-
cal success in MRSA-infected patients with high trough 
levels being 1.71 times higher than in patients with low 
trough levels.
Discussion
Association between vancomycin trough levels and 
nephrotoxicity was largely uniform across the stud-
ies included in this meta-analysis; however incidence of 
vancomycin-induced nephrotoxicity varied from study 
to study. Nephrotoxicity rates in the high and low trough 
groups varied from 18 to 55 % and 0 to 29 %, respectively. 
This variability was due to varying baseline levels among 
the study population, length of vancomycin therapy, 
receipt of other nephrotoxic agents, and renal function 
(creatinine clearance). From the 19 studies in this anal-
ysis, the study in patients with any type of nosocomial 
MRSA infection had the lowest nephrotoxicity rate [30] 
while the study in patients with MRSA HCAP had the 
highest nephrotoxicity rate in both trough level groups 
[31]. Patients in the study with the highest rate of nephro-
toxicity had higher APACHE II scores and received more 
concomitant nephrotoxic agents than patients in all other 
studies. These results support the finding of some other 
studies that concomitant nephrotoxic agents were a risk 
factor for renal function impairment during vancomycin 
therapy [30–32]. The meta-analysis by van Hal and col-
leagues [22] found nephrotoxicity rates that varied from 
7 to 67 % in the high trough group (≥15 mg/L) and from 
0 to 33 % in the low trough group (<15 mg/L), which both 
ranges exceeding those from our study. Nephrotoxic-
ity ranges in the van Hal, et al. meta-analysis were wider 
than the ranges in this study due to some differences of 
the included studies and no limitation regarding the type 
of MRSA infection included in their study.
Clinical success was extremely variable across the stud-
ies in this analysis with most differences between high 
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There was two exceptions [17, 33], however, with success 
rates ranging from 24 to 82 % and 39 to 87 % for high and 
low trough groups, respectively. This variability was due 
to baseline clinical status of study population and sites of 
MRSA infections. In the present meta-analysis, the stud-
ies with the most patients infected with MRSA pneumo-
nia had low clinical success rates ranging from 24 to 54 % 
[34, 35]. MRSA-infected patients in the intensive care 
unit (ICU) were also more likely to have poor clinical 
success with vancomycin therapy, as compared to non-
ICU MRSA-infected patients [36, 37].
Mortality rate also varied widely across the stud-
ies in this analysis, ranging from 5 to 20  % in most of 
the studies and from 36 to 47 % in two studies [36, 38]. 
No statistically significant differences were observed 
between high and low trough groups. Patients who had 
either MRSA bacteremia or who required intensive care 
had higher mortality rates. The results of this meta-anal-
ysis support the results of previous studies [15, 39], all 
finding that there is no evidence supporting association 
between higher vancomycin trough levels and improved 
outcome in patients with MRSA. Although we had origi-
nally planned to conduct analysis using a meta-regression 
model to investigate possible sources of heterogeneity of 
clinical success among the studies, sufficient data were 
not available to conduct this analysis.
Based on our review of the literature, this study is the 
first meta-analysis to compare the safety and efficacy of 
Fig. 2 Forest plot of the odds ratio (OR [95 % confidence interval]) for the effect of vancomycin trough levels on nephrotoxicity between high and 
low trough levels
Fig. 3 Forest plot of the odds ratio (OR [95 % confidence interval]) for the effect of vancomycin trough levels on mortality between high and low 
trough levels
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high vs. low vancomycin trough levels in MRSA-infected 
patients that were treated according to the current 
guidelines for treating MRSA infections. The results of 
this analysis also confirm the results of previous stud-
ies that were not included in this meta-analysis, which 
showed that higher vancomycin trough levels (or higher 
vancomycin doses) were associated with increase risk 
of nephrotoxicity [8, 30, 40–46]. Considerable contro-
versy exists concerning the relationship between van-
comycin MICs and clinical outcomes. Several studies 
have reported association between higher vancomycin 
MIC and increased risk of treatment failure or mortal-
ity [30, 47–54], with others finding no significant asso-
ciation with poor outcomes [37, 55–59]. However, recent 
Fig. 4 Forest plot of the odds ratio (OR [95 % confidence interval]) for the effect of vancomycin trough levels on clinical success between high and 
low trough levels
Fig. 5 Influence analysis with forest plots of odds ratio (OR) for a nephrotoxicity; b mortality; and c clinical success
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meta-analysis study in high vancomycin MIC and clini-
cal outcomes in adults with MRSA infections by Jacob 
and DiazGranados [60] found that high vancomycin MIC 
was associated with increased mortality and treatment 
failure.
In this study, the random effects model was used to 
combine the odds ratios for the outcomes of interest, 
even though there was no evidence of heterogeneity. 
The decision to use the random effects model was made 
a priori, depending upon the nature of the eligible stud-
ies and our goals for the following reasons: individual 
eligible studies were collected from several independent 
studies; included studies were heterogeneous for study 
design; and, inferences based on the random effects 
model can be generalized beyond the studies included in 
the meta-analysis.
This study has several notable strengths. First, studies 
that were included in this meta-analysis were independ-
ent studies that were conducted during different periods 
of observation. The results, both individually and collec-
tively, strongly support the fact that there is evidence that 
higher trough levels are more harmful than low trough 
levels in terms of nephrotoxicity. Secondly, the results of 
influence analysis on all outcomes in which each study 
was removed from the analysis one by one to determine 
the magnitude of influence on overall effect size, showed 
that overall effect size was relatively independent of any 
one particular study. Third, adjusting for asymmetric 
funnel plots using the trim and fill method did not sig-
nificantly change the results of this meta-analysis for 
nephrotoxicity and mortality, indicating that the missing 
studies were unlikely to have changed the conclusions 
relating to these outcomes. However, the results of trim 
and fill analysis showed substantial impact of publication 
bias on the conclusion for clinical success. Specifically, 
after trim and fill, the association between high trough 
level and clinical success was no longer non-significant. 
Finally, the conclusions of the present meta-analysis were 
similar to the conclusions from our exploratory meta-
analysis that included the excluded 112 patients that had 
vancomycin trough levels of >20 mg/L.
This study also has some mentionable limitations. First, 
the definition of mortality and/or clinical success var-
ied slightly among some of the studies included in this 
meta-analysis, according to the stated protocol of each 
study. Second, this meta-analysis included a combina-
tion of different study designs, including: nine retrospec-
tive cohort studies, four prospective cohort studies, two 
retrospective studies, one non-randomized compara-
tive study, one retrospective quasi-experimental study, 
one prospective surveillance study, and one multicenter 
prospective study. Third, only one study met the criteria 
Fig. 6 a Funnel plot for nephrotoxicity after adjusting for missing studies using the trim and fill method; b Symmetrical funnel plot for mortality 
with an absence of evidence for asymmetry; c Funnel plot for clinical success after adjusting for missing studies using the trim and fill method (filled 
circles are original data and open circles represent estimated missing studies)
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for combining adjusted OR from different studies for the 
outcomes of clinical success and mortality; thus, these 
analyses were not performed. Finally, we did not evaluate 
the other factors that might associate with high vanco-
mycin trough levels due to lack of information.
The inclusion of grey literature that meets the prede-
fined inclusion criteria of a meta-analysis may help to 
reduce the effect of publication bias and/or funnel plot 
asymmetry, whereas the exclusion of grey literature could 
lead to bias, most notably the overestimation of effect 
sizes [61, 62]. The research cited in published reviews 
demonstrates that studies published in journals have a 
tendency to report larger effect sizes than studies pub-
lished in grey literature [63, 64].
Conclusion
Based on pooled adjusted OR, high vancomycin trough 
level is the variable that was identified as the independ-
ent factor associated with risk of nephrotoxicity in MRSA 
infections. MRSA-infected patients with trough levels 
≥15 mg/L had greater odds of nephrotoxicity than those 
with trough levels <15  mg/L. There was no evidence of 
difference in mortality or clinical success between patients 
with trough levels ≥15 and <15 mg/L. However, we need 
to acknowledge that this conclusion does not take into 
account vancomycin MIC data, which were not available 
for analysis in this study. Since adjustment of funnel plot 
asymmetry using the trim and fill method yielded signifi-
cant change in pooled OR for clinical success, association 
between high vancomycin trough levels and both risk for 
adverse events and improvement in clinical outcomes in 
patients with MRSA infection requires further study.
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